15
Cancer Biochemistry

Biochemistry cancer

Embed Size (px)

DESCRIPTION

about the tumor marker on the cancer progression and diagnosis

Citation preview

Page 1: Biochemistry cancer

Cancer Biochemistry

Page 2: Biochemistry cancer

Tumour marker

• Any substance that can be related to the presence or progress of a tumour.

• Hormones: human gonadotrophin (HCG) secreted by choriocarcinoma

• Enzymes: prostate specific antigen (PSA) in prostate carcinoma

• Tumour antigens: carcinoembryonic antigen (CEA) in colorectal carcinoma

Page 3: Biochemistry cancer
Page 4: Biochemistry cancer
Page 5: Biochemistry cancer

The use of tumour markers

Monitoring treatment• Surgery, chemotherapy, radiotherapy

Assessing follow-up• To monitor the marker long after the levels have

appeared to stabilized

Diagnosis• Detection in blood, biopsy

Page 6: Biochemistry cancer

Prognosis• To be of value in prognosis, the

concentration of the tumour marker in plasma should be correlate with tumour mass.

• Eg: HCG correlates well with the tumour mass in choriocarcinoma

• HCG and AFP correlate with the tumour mass in testicular teratoma

• Paraproteins correlate with the tumour mass in multiple myeloma.

Page 7: Biochemistry cancer

Screening for the presence of disease• Specific high-risk population• Eg: hormone calcitonin, which is

increased in all patients with medullary carcinoma of thyroid, may be used to screen close relatives.

Page 8: Biochemistry cancer

The important tumour markers:

• Alkaline phosphatase (ALP)• Lactate dehydrogenase (LDH)• Prostatic acid phosphatase (PAP)• Prostate specific antigen (PSA)• Human chorionic gonadotropin (HCG)• Alpha-fetoprotein (AFP)• Carcino-embryonic antigen (CEA)

Page 9: Biochemistry cancer

• CA-15 : marker for breast carcinomas• CA-125 : marker for ovarian and

endometrial carcinoma• Calcitonin (secreted by cells of thyroid

gland. Increased in medullary tumour of thyroid gland)

*carcinoma: cancer arising from epithelial tissue.

sarcoma: cancer from connective tissue

Page 10: Biochemistry cancer

• ALP- Primary or secondary liver cancer- Secondary bone cancer- Lung cancer- Cancer of GIT and ovary- Hodgkin’s disease

Page 11: Biochemistry cancer

• PAP-malignant conditions: cancer of prostate,

multiple myeloma, osteogenic sarcoma.-benign conditions: prostatic hypertrophy

(BPH) or enlarged prostate, osteoporosis and hyperparathyroidism.

• PSA-superior marker for prostatic cancer.

Page 12: Biochemistry cancer

• Human Chorionic Gonadotropin (HCG)-placental hormon. Synthesized by

syncytiotrophoblastic cells of placental villi.-choriocarcinoma. About 50% of cases of

choriocarcinoma follow hydatidiform mole pregnancy and HCG is used to screen these women.

-ideal tumour marker for diagnosing and monitoring gestational trophoblastic tumours and germ cell tumours of testes and ovary.

Page 13: Biochemistry cancer

• Alpha-Feto Protein (AFP)-like CEA, AFP is another oncofetal antigen.

AFT is synthesized in liver, yolk sac and GI tract in fetal life and released into serum of fetus.

-AFP is the more specific and ideal tumour marker for primary carcinoma of the liver (hepatocellular carcinoma)

-serum AFP and HCG are best available tumour markers for germ cell type of tumours.

Page 14: Biochemistry cancer

• Cancer antigen 125 (CA-125)-used for screening and diagnosis of ovarian

carcinoma-not specific for ovarian carcinoma

• CA 15-3 & CA-27.29- useful as tumour marker in breast carcinoma

• CA 19-9-useful as tumour marker in pancreatic cancer

and biliary tract cancers.

Page 15: Biochemistry cancer

Hormones

• produced by many tumors• natural product or represent abnormal

synthesis• eg: insulin by islet cell tumor, calcitonin by

medullary thyroid carcinoma, catecholamines by pheochromocytoma

• ectopic hormones - ACTH and ADH by lung cancer